Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201264 | 0.81 | AGXT (0.39) | TAAR1IDO1 | |
| SCHEMBL15802699 | 0.81 | EPHX1 (0.56) | TAAR1SLC7A5SLC6A2 | |
| SCHEMBL17264165 | 0.81 | CSK (0.50) | SLC7A5 | |
| SCHEMBL12015253 | 0.77 | SLC6A4 (0.32) | — | |
| SCHEMBL14666766 | 0.76 | NQO1 (0.45) | — | |
| SCHEMBL14666765 | 0.76 | ITGB3 (0.35) | — | |
| SCHEMBL21350258 | 0.75 | PTPN1 (0.35) | — | |
| SCHEMBL1013284 | 0.75 | TAAR1 (0.55) | TAAR1SLC7A5SLC6A2ESR1ESR2 | |
| SCHEMBL4394050 | 0.75 | TAAR1 (0.61) | TAAR1SLC7A5SLC6A2IDO1ESR1 | |
| SCHEMBL1013285 | 0.75 | TAAR1 (0.55) | TAAR1SLC7A5SLC6A2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20160376579-A1 | NEW ENZYMES AND METHOD FOR PREPARING 4-HYDROXYL BENZYL ALCOHOL AND DERIVATIVES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064819-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | TAAR1 3408/4885SLC7A5 3028/4885SLC6A2 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.